Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: The Uppsala Women's Cohort Study

Sexually Transmitted Infections

Volumn 82, Issue 3, 2006, Pages 212-218

  Low, Nicola ^a,b   Egger, M ^a   Sterne, J A C ^b   Harbord, R M ^b   Ibrahim, F ^b   Lindblom, B ^c   Herrmann, B ^d  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BACTERIUM IDENTIFICATION; CHLAMYDIA; CHLAMYDIASIS; CONTROLLED STUDY; DISEASE SEVERITY; ECTOPIC PREGNANCY; EDUCATION; FEMALE; FEMALE INFERTILITY; FOLLOW UP; GENITAL TRACT INFECTION; HEALTH BEHAVIOR; HEALTH PROGRAM; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PELVIC INFLAMMATORY DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; CHLAMYDIA INFECTIONS; EPIDEMIOLOGIC METHODS; FEMALE; GENITAL DISEASES, FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; MASS SCREENING; SWEDEN;

EID: 33745140867     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2005.017186     Document Type: Article

References (40)

1. Cotes W Jr, Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991;164:1771-81.
2. Weström L. Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol 1975;121:707-13.
3. Weström L, Bengtsson LP, Mårdh PA. Incidence, trends, and risks of ectopic pregnancy in a population of women. BMJ 1981;282:15-18.
4. Weström L, Joesoef R, Reynolds G, et al. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 057 control women with normal laparoscopic results. Sex Transm Dis 1992;19:185-92.
5. Health Protection Agency. Chlamydia. http://www.hpa.org.uk/infections/ topics_az/hiv_and_sti/sti-chlamydia/chlamydia.htm, 2005. Accessed 5 July, 2005.
6. The National Woman's Health Information Center. Chlamydia. http://www.4woman.gov/faq/stdchlam.htm4woman.gov. US Department of Health and Human Services, 2005.
7. Low N, Egger M. What should we do about screening for genital chlamydia? Int J Epidemiol 2002;31:891-3.
8. Van Valkengoed IG, Morré SA, van den Brule AJ, et al. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes-implications for cost-effectiveness analyses. Int J Epidemiol 2004;33:416-25.
9. Simms I, Warburton F, Weström L. Diagnosis of pelvic inflammatory disease: time for a rethink. Sex Transm Infect 2003;79:491-4.
10. Clark KI, Howell MR, Li Y, et al. Hospitalization rates in female US Army recruits associated with a screening program for Chlamydia trachomatis. Sex Transm Dis 2002;29:1-5.
11. Ostergaard L, Andersen B, Møller JK, et al. Home sampling versus conventional swab sampling for screening of chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. Clin Infect Dis 2000;31:951-7.
12. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996;334:1362-6.
13. Simms I, Rogers P, Charlett A. The rate of diagnosis and demography of pelvic inflammatory disease in general practice: England and Wales. Int J STD AIDS 1999;10:448-51.
14. Rothman KJ, Lanza L, Lal A, et al. Incidence of pelvic inflammatory disease among women treated for gonorrhea or chlamydia. Pharmacoepidemiol Drug Saf 1996;5:409-14.
15. Andersen B, Østergaard L, Puho E, et al. Ectopic pregnancies and reproductive capacity after Chlamydia trachomatis positive and negative test results: a historical follow-up study. Sex Transm Dis 2005;32:377-81.
16. Kamwendo F, Forslin L, Bodin L, et al. Programmes to reduce pelvic inflammatory disease - the Swedish experience. Lancet 1998;351(Suppl) 3:25-8.
17. Herrmann B, Egger M. Genital Chlamydia trachomatis infections in Uppsala County, Sweden, 1985-1993: declining rates for how much longer? Sex Transm Dis 1995;22:253-60.
18. Low N. Current status of chlamydia screening in Europe. Eurosurveillance 2004;8:5.
19. Low N, Harbord RM, Egger M, et al. Screening for chlamydia. Lancet 2005;365:1539,
20. Johnson RE, Newhall WJ, Papp JR, et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeas infections - 2002. Morb Mort Wkly Rep Recomm Rep 2002;51:1-38.
21. Parker J, Bisits A, Proietto AM. A systematic review of single-dose intramuscular methotrexate for the treatment of ectopic pregnancy. Aus N Z J Obstet Gynaecol 1998;38:145-50.
22. Chen MY, Fairley CK, Donovan B. Discordance between trends in chlamydia notifications and hospital admission rates for chlamydia related diseases in New South Wales, Australia. Sex Transm Infect 2005;81:318-22.
23. Chen MY, Pan Y, Britt H, et al. Trends in clinical encounters for pelvic inflammatory disease and epididymitis in a national sample of Australian general practices. Int J STD AIDS 2005;(in press).
24. Wiesenfeld HC, Sweet RL, Ness RB, et al. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis 2005;32:400-5.
25. Low N. Chlamydia (uncomplicated, genital). http://www.clinicalevidence. com/ceweb/conditions/seh/1607/1607.jsp, 2005.
26. Weström L, Eschenbach D. Pelvic inflammatory disease. In: Holmes KK, Mardh P-A, Sparling PF, et al. Sexually transmitted diseases. New York: McGraw-Hill, 1999.
27. Stamm WE, Guinan ME, Johnson C, et al. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med 1984;310:545-9.
28. Duncan B, Hart G, Scoular A, et al. Qualitative analysis of psychosocial impact of diagnosis of Chlamydia trachomatis: implications for screening. BMJ 2001;322:195-9.
29. Hillis SD, Owens LM, Marchbanks PA, et al. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997;176:103-7.
30. Paavonen J, Puolakkainen M, Paukku M, et al. Cost-benefit analysis of first-void urine Chlamydia trachomatis screening program. Obstet Gynecol 1998;92:292-8.
31. Hu D, Hook EW III, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Ann Intern Med 2004;141:501-13.
32. Handsfield HH. Screening asymptomatic women for Chlamydia trachomatis: abstract and commentary. JAMA 1998;280:1800-1.
33. Washington AE, Arno PS, Brooks MA. The economic cost of pelvic inflammatory disease. JAMA 1986;255:1735-8.
34. Golden MR, Schillinger JA, Markowitz L, et al. Duration of untreated genital infections with Chlamydia trachomatis: a review of the literature. Sex Transm Dis 2000;27:329-37.
35. Morré SA, van den Brule AJ, Rozendaal L, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS 2002;13(Suppl 2):12-8.
36. Molano M, Meijer CJ, Weiderpass E, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis 2005;191:907-16.
37. Roberts T, Robinson S, Barton P, et al. The correct approach to modelling and evaluating chlamydia screening. Sex Transm Infect 2004;80:324-a.
38. Weite R, Postma M, Leidl R, et al. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis 2005;32:474-83.
39. Miller WC. Screening for chlamydial infection: are we doing enough? Lancet 2005;365:456-8.
40. Levine WC, Dicker LW, Devine O, et al. Indirect estimation of chlamydia screening coverage using public health surveillance data. Am J Epidemiol 2004;160:91-6.